If you are wondering whether Biogen's current share price reflects its true worth, you are not alone. This article is built to help you frame that question clearly. Biogen recently closed at US$183.38 ...

Biogen (BIIB) stock is in focus as the company beats forecasts with its Q1 2026 financials and trims its full-year earnings ...

While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to ...

Biogen BIIB reported upbeat earnings for the first quarter on Wednesday. The company posted quarterly earnings of $3.57 per ...

Biogen lowered its earnings guidance and projected weaker revenue for 2026, tempering the impact of a first-quarter rise in both sales and profit.

Biotech company Biogen (NASDAQ:BIIB) reported in Q1 CY2026, with sales up 1.9% year on year to $2.48 billion. Its non-GAAP ...

Biogen (NASDAQ:BIIB | BIIB Price Prediction) stock just earned a strong endorsement from Wells Fargo on Monday, as analyst ...

On Apellis, "we have the proposed Apellis acquisition" and "we do expect the acquisition to be accretive in 2027" (CEO Viehbacher). "Total revenue was $2.5 billion" and "non-GAAP diluted EPS of $3.57" ...

The market expects Biogen Inc. (BIIB) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus ...

Patient Capital Management, a value investing firm, released its “Patient Opportunity Equity Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, ...

Biogen Inc (NASDAQ:BIIB) reflects mixed sentiment as Nasdaq composite trends highlight biotech sector dynamics.